UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): May 30, 2012
AVEO Pharmaceuticals, Inc.
(Exact Name of Registrant as Specified in Charter)
| Delaware | 001-34655 | 04-3581650 | ||
| (State or Other Jurisdiction of Incorporation) |
(Commission File Number) |
(IRS Employer Identification No.) | ||
| 75 Sidney Street Cambridge, Massachusetts |
02139 | |||
| (Address of Principal Executive Offices) | (Zip Code) | |||
Registrant’s telephone number, including area code: (617) 299-5000
(Former Name or Former Address, if Changed Since Last Report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
| ¨ | Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
| ¨ | Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
| ¨ | Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
| ¨ | Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Item 5.07 Submission of Matters to a Vote of Security Holders.
At the annual meeting of shareholders of AVEO Pharmaceuticals, Inc. (the “Company”) held on May 30, 2012, the Company’s shareholders voted on the following proposals:
1. The following nominees were elected to the Company’s Board of Directors for terms expiring at the 2013 annual meeting of shareholders.
| For | Withheld | Broker Non-Votes | ||||||||||
| Mr. Kenneth Bate |
33,585,100 | 150,035 | 4,356,839 | |||||||||
| Dr. Ronald DePinho |
33,623,051 | 112,084 | 4,356,839 | |||||||||
| Dr. Anthony Evnin |
33,708,223 | 26,912 | 4,356,839 | |||||||||
| Mr. Tuan Ha-Ngoc |
33,670,381 | 64,754 | 4,356,839 | |||||||||
| Dr. Raju Kucherlapati |
33,662,626 | 72,509 | 4,356,839 | |||||||||
| Mr. Henri Termeer |
33,579,070 | 156,065 | 4,356,839 | |||||||||
| Mr. Kenneth Weg |
19,084,041 | 14,651,094 | 4,356,839 | |||||||||
| Dr. Robert Young |
33,707,123 | 28,012 | 4,356,839 | |||||||||
2. A non-binding, advisory proposal on the compensation of the Company’s named executive officers was approved.
| For: |
33,471,047 | |||
| Against: |
256,138 | |||
| Abstain: |
7,950 | |||
| Broker Non-Votes: |
4,356,839 |
3. The appointment of Ernst & Young LLP as the independent registered public accounting firm for the Company for the fiscal year ending December 31, 2012 was ratified.
| For: |
37,919,378 | |||
| Against: |
160,724 | |||
| Abstain: |
11,872 |
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
| AVEO Pharmaceuticals, Inc. | ||||||
| Date: June 4, 2012 | By: | /s/ David B. Johnston | ||||
| David B. Johnston Chief Financial Officer | ||||||